Information Provided By:
Fly News Breaks for April 20, 2015
INCY
Apr 20, 2015 | 08:47 EDT
SunTrust increased its price target on Incyte after proof-of-concept preclinical data for Incyte's INCB5429 BET inhibitor in myeloma was unveiled. The firm says that the BET inhibitor has potent preclinical activity in myeloma, both as a single agent and in combination. Suntrust adds that the inhibitor could be suitable to combinations with several of Incyte's later stage portfolio drugs. It keeps a Buy rating on the shares.
News For INCY From the Last 2 Days
There are no results for your query INCY